Journal article
Canadian Consensus Recommendations on the Management of MET-Altered NSCLC
Abstract
In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatments. These variations, together with the emergence of several novel mesenchymal-epithelial transition (MET) factor-targeted therapies for the treatment of NSCLC, warrant the development of …
Authors
Cheema PK; Banerji SO; Blais N; Chu QS-C; Desmeules P; Juergens RA; Leighl NB; Sheffield BS; Wheatley-Price PF; Melosky BL
Journal
Current Oncology, Vol. 28, No. 6, pp. 4552–4576
Publisher
MDPI
DOI
10.3390/curroncol28060386
ISSN
1198-0052